Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Ionis Pharmaceuticals has a planned insider sale of 8,480 shares of its common stock under Rule 144. The shares are expected to be sold through Morgan Stanley Smith Barney on or about January 16, 2026, with an aggregate market value of $646,375.84, on the NASDAQ exchange.
The securities were acquired on January 15, 2026 as RSUs granted under the company’s 2011 Equity Incentive Plan, classified as compensation. The filing notes that 161,137,930 shares of common stock were outstanding, giving context for the size of this planned transaction.
Ionis Pharmaceuticals has a holder filing a notice of proposed sale of 12,922 shares of common stock, with an aggregate market value of $985,108.70. The shares are expected to be sold through Morgan Stanley Smith Barney on the NASDAQ around 01/16/2026. Ionis common shares outstanding were 161,137,930 at the time referenced. The seller acquired these 12,922 shares on 01/15/2026 as performance stock units granted under the company’s 2011 Equity Incentive Plan, treated as compensation.
Ionis Pharmaceuticals is the issuer of common stock that a holder plans to sell under Rule 144. The notice covers the planned sale of 44,034 shares of common stock through Morgan Stanley Smith Barney on or about 01/16/2026 on the NASDAQ market, with an aggregate market value of $3,357,167.26. These shares were acquired on 01/15/2026 as RSUs granted under the 2011 Equity Incentive Plan, treated as compensation. As context, 161,137,930 shares of this class were outstanding at the time stated.
Ionis Pharmaceuticals has a planned insider sale of common stock reported under Rule 144. The filing covers the potential sale of 4,141 shares of Ionis common stock through broker Morgan Stanley Smith Barney, with an aggregate market value of $315,484.80. The notice lists total common shares outstanding as 161,137,930 and identifies NASDAQ as the exchange where the shares are to be sold. The securities were acquired as RSUs granted under the 2011 Equity Incentive Plan and treated as compensation.
An individual associated with Ionis Pharmaceuticals has filed a notice of proposed sale of restricted securities under Rule 144. The filer plans to sell 9,191 shares of Ionis common stock through Morgan Stanley Smith Barney on the NASDAQ, with an indicated aggregate market value of $700,602.62 at the time of the notice. Ionis had 161,137,930 common shares outstanding when this notice was prepared.
The shares to be sold are common stock acquired on 01/15/2026 as RSUs granted under the 2011 Equity Incentive Plan, described as compensation. The planned sale date is listed as 01/16/2026. By signing the notice, the seller represents that they are not aware of any material adverse, non-public information about Ionis Pharmaceuticals.
A holder of Ionis Pharmaceuticals common stock filed a notice of proposed sale under Rule 144 for 9,302 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of 01/16/2026 and an aggregate market value of 709071.67.
The securities were acquired on 01/15/2026 as RSUs granted under the 2011 Equity Incentive Plan, treated as compensation, in the same amount of 9,302 shares. The filing notes that 161,137,930 shares of the issuer’s common stock were outstanding, providing context for the planned sale.
Ionis Pharmaceuticals filed a notice of proposed insider share sales under Rule 144. The filing covers 1,823 shares of common stock to be sold through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $138,963.60. The issuer reports 161,137,930 shares of common stock outstanding.
The shares to be sold were acquired as restricted stock units granted under the company’s 2011 Equity Incentive Plan and treated as compensation, with both the grant and payment dated 01/15/2026. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about Ionis Pharmaceuticals’ operations.
Ionis Pharmaceuticals insider plans another stock sale under Rule 144. A holder has filed to sell 8,353 shares of Ionis common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $636,626.29. These shares were acquired on 01/15/2026 as restricted stock units granted under the company’s 2011 Equity Incentive Plan and treated as compensation.
The notice also lists recent sales in the past three months for the same account holder. Shannon Devers sold 16,777 shares of common stock on 11/25/2025 for gross proceeds of $1,342,160.00, and 44,199 shares on 01/07/2026 for gross proceeds of $3,760,522.76 through Stifel Nicolaus & Company Inc. The filer represents that they are not aware of undisclosed material adverse information about Ionis.
Ionis Pharmaceuticals, Inc. reported preliminary 2025 U.S. net product sales of $105 million for its drug TRYNGOLZA. These figures are unaudited, may be adjusted, and are being shared ahead of the company’s full financial results, which are planned for February 2026. The sales number gives an early view of TRYNGOLZA’s commercial performance in the U.S. market but does not represent the company’s complete 2025 financial picture.
Ionis Pharmaceuticals' EVP and Chief Human Resources Officer, Shannon L. Devers, reported a series of option exercises and share sales on January 7, 2026. Devers exercised several non-qualified stock options to acquire common stock at exercise prices of $32.60, $37.58, $52.87, and $56.78, then sold the resulting shares in market transactions. Blocks sold included 25,545 shares at a weighted average price of $85.36 and 9,264 shares at a weighted average price of $84.62, among other trades. After these transactions, Devers directly held 17,494 shares of Ionis common stock. The sales were made under a Rule 10b5-1 trading plan adopted on September 3, 2024.